Status:
COMPLETED
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Lead Sponsor:
R-Pharm
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to hi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced disease that is not surgically resectable, or distant metastatic disease)
- Participants must have measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines
- Participants must not have received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreas cancer
- Karnofsky performance status (KPS) of 70-100
- Adequate hematologic, hepatic and renal function
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00383149
Start Date
January 1 2007
End Date
June 1 2009
Last Update
March 10 2016
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Georgetn Univ Lombardi Can Ctr
Washington D.C., District of Columbia, United States, 20007
2
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
3
University Of Miami
Miami, Florida, United States, 33136
4
University Of Michigan
Ann Arbor, Michigan, United States, 48109